Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Author(s) -
Sara Thietart,
Alexandre Karras,
JeanFrançois Augusto,
Carole Philipponnet,
PierreLouis Carron,
X. Delbrel,
Rafik Mesbah,
Thomas Gille,
P. Duffau,
Khalil El Karoui,
P. Smets,
Jonathan London,
Luc Mouthon,
Loı̈c Guillevin,
Benjamin Terrier,
Xavier Puéchal,
French Vasculitis Study Group,
Asma Alla,
Vincent Audard,
O. Aumaître,
Stéphane Bally,
Bernard Bonnotte,
Pierre Charles,
Pascal Cohen,
Alice Corbel,
Maud Cousin,
Yoann Cabrol,
S. Durupt,
B. Faucher,
Ségolène Gendreau,
N. Girszyn,
Pascal Godmer,
M. Hamidou,
Noémie JourdeChiche,
Adeline Lacraz,
C. Landron,
Claire Le Jeunne,
François Lifermann,
É. Liozon,
S. MarchandAdam,
Arnaud François,
A. Mékinian,
Christian Pagnoux,
T. Quéméneur,
V. Queyrel,
Hanta Nirina Rakotoarivelo,
Alexis Régent,
Quitterie Reynaud,
V. Rieu,
Karim Sacré,
André Soto,
Dimitri TitecaBeauport,
S. Vinzio
Publication year - 2022
Publication title -
jama network open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.278
H-Index - 39
ISSN - 2574-3805
DOI - 10.1001/jamanetworkopen.2022.20925
Subject(s) - rituximab , medicine , vasculitis , microscopic polyangiitis , granulomatosis with polyangiitis , maintenance therapy , adverse effect , anti neutrophil cytoplasmic antibody , discontinuation , chemotherapy , disease , lymphoma
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom